SureTrader Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Buckden, BooDog, Nadendla, BERKSHIRE AGENT , The Apostle
Search This Board:
Last Post: 11/25/2015 11:57:00 PM - Followers: 207 - Board type: Free - Posts Today: 0




"The Future Of Medicine"


Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 


Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 

Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697


Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.

Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options





Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.

Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective. 

Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).

The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.

Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug

November 19, 2014
Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCQB: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a.  Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a.  Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization.  Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.  “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound”, said James Leresche, Ph.D., Head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).  Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.  The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,
Lonza Media Contacts:
Colleen Floreck, +1 201 316 9290,
Constance Ward, +41 61 316 8840,
Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.

Nansha China

Visp Switzerland

SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals

We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

Intellectual Property

We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
Advanomics Corporation, the Parent Company of Sunshine Biopharma

Head Office:

Advanomics Corporation

2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8

Tel: 514-764-9698
Fax: 514-764-9699

Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,

Product Pipeline

Our product pipeline is comprised of the following anti-tumor compounds:


Entering Phase I later this year (Lead Compound)



RNAi Anti-Cancer drug candidate
Soon to enter animal studies phase



Currently in preclinical phase


SBFM Share Structure

From and SEC filings
The number of shares of the registrant’s only class of common stock issued and outstanding as of November 10, 2014, was 68,911,041 shares.

Authorized Shares 200,000,000 a/o Dec 31, 2011

31.5 million held by Steve Slilaty, CEO

SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Tel: 514-764-9698
Fax: 514-764-9699






  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
SBFM News: Quarterly Report (10-q) 11/04/2015 02:45:13 PM
SBFM News: Current Report Filing (8-k) 10/09/2015 12:55:42 PM
SBFM News: Quarterly Report (10-q) 08/06/2015 04:15:25 PM
SBFM News: Current Report Filing (8-k) 08/04/2015 11:06:26 AM
SBFM News: Information Statement - All Other (definitive) (def 14c) 06/23/2015 06:04:28 AM
#20240  Sticky Note $360K a year for 12 years using SHAREHOLDERS BooDog 10/16/15 06:04:54 AM
#11692  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 10/09/13 10:52:01 AM
#21422   Nice here's to a day off tomorrow and Buckeye00 11/25/15 11:57:00 PM
#21421   Huge news should be hitting soon, SILVER will gh0st 11/25/15 10:57:03 PM
#21420   Thanks SILVER HARVEST. Agree it would be BERKSHIRE AGENT 11/25/15 08:47:59 PM
#21419   Great call Berk Silver city would be great SILVER HARVEST 11/25/15 06:15:35 PM
#21418   The last big run ran to SILVER around BERKSHIRE AGENT 11/25/15 06:12:54 PM
#21417   SILVER would be awesome! GO SBFM gh0st 11/25/15 06:07:20 PM
#21416   Agree that's exactly what I'm seeing. Personaly BERKSHIRE AGENT 11/25/15 05:59:05 PM
#21415   indeed, thinking this hits a penny then has gh0st 11/25/15 05:17:22 PM
#21414   SBFM~~~~> POTENTIAL= MIND BLOWING $$$$$$$$$$$$$$$$$$ BERKSHIRE AGENT 11/25/15 05:06:49 PM
#21413   SBFM awesome green close $$$ BERKSHIRE AGENT 11/25/15 04:46:42 PM
#21412   Buddy , I've been posting on this board reginaliberta 11/25/15 04:24:04 PM
#21411   What's the matter did not get your lower viper666 11/25/15 03:47:51 PM
#21410   A price tag of 1/2 penny per share rverboatgambler 11/25/15 03:27:14 PM
#21409   Do bashers get holiday pay tomorrow? dtdsmd05 11/25/15 03:21:21 PM
#21407   What is this wasted energy going into sbfm.... reginaliberta 11/25/15 03:15:10 PM
#21405   Don't know I'm in it and taking the Buckeye00 11/25/15 02:54:01 PM
#21404   Any truth to the rumor of an epic rverboatgambler 11/25/15 02:53:11 PM
#21403   Talk to u al Friday. Remember it's a Buckeye00 11/25/15 02:28:32 PM
#21402   Bid support building at 46, 45 seems to SooS416 11/25/15 01:17:30 PM
#21401   AGREE Tonyeight 11/25/15 01:07:26 PM
#21400   long and strong load up gh0st 11/25/15 01:00:15 PM
#21399   Strong like a bull here. Strong hands going BERKSHIRE AGENT 11/25/15 12:56:46 PM
#21398   Lol, im a little lower. ;) just having jlax 11/25/15 12:54:47 PM
#21397   that you with the 1M bid at 4, SooS416 11/25/15 12:51:22 PM
#21396   Ouch. jlax 11/25/15 12:49:34 PM
#21394   Testing support at 45 SooS416 11/25/15 12:46:03 PM
#21393   Ready for next leg up cdel moved to .0065 ActiveMoney1 11/25/15 12:33:23 PM
#21392   SBFM looking great gh0st 11/25/15 12:18:41 PM
#21391   You're charting a penny stock on a holiday Insidiou$ 11/25/15 12:13:31 PM
#21390   I have no problem suing you for that Insidiou$ 11/25/15 12:13:07 PM
#21389   Little premature, it is still green on the SooS416 11/25/15 12:11:54 PM
#21388   Not once has it held middle BB support jlax 11/25/15 12:02:55 PM
#21387   Lol, timber!! Like I said, the group on jlax 11/25/15 11:57:19 AM
#21386   What's funny to me is watching these retailers Insidiou$ 11/25/15 11:55:45 AM
#21385   I'm here been holding going long hold on viper666 11/25/15 11:53:39 AM
#21384   I'm in. Got bamboozled on the last play. Buckeye00 11/25/15 11:48:46 AM
#21383   Who is CDEL here.. could you please raise Nadendla 11/25/15 11:46:15 AM
#21382   SBFM.. Potential to reach revenues of a Billion Nadendla 11/25/15 11:45:21 AM
#21381   yup.. who knows who these posters are .. Nadendla 11/25/15 11:43:10 AM
#21380   I understand.. but I never give up..I learnt Nadendla 11/25/15 11:41:50 AM
#21379   Thats what i am saying.. look at the Nadendla 11/25/15 11:40:16 AM
#21378   Thanks and 100% agree RON ACTIVE! Real deal BERKSHIRE AGENT 11/25/15 11:25:55 AM
#21376   Solid Post !!! It's an obvious buyout opportunity ActiveMoney1 11/25/15 10:58:58 AM
#21375   Nice. Win win here. We make $$ and Buckeye00 11/25/15 10:57:48 AM
#21374   SBFM~~~~> Must See~~~~> We believe that upon successful BERKSHIRE AGENT 11/25/15 10:52:04 AM
#21373   Accurate post Ron. Who knows who these BooDog 11/25/15 10:51:58 AM
#21372   Ask getting slappeddd ActiveMoney1 11/25/15 10:51:02 AM
#21371   The company said they were filing their IND ronpopeil 11/25/15 10:49:54 AM
#21370   Good luck to you. I really hope you ronpopeil 11/25/15 10:48:06 AM
#21369   Medical stocks take time.. it's not an overnight ActiveMoney1 11/25/15 10:46:45 AM